MX345830B - Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. - Google Patents

Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.

Info

Publication number
MX345830B
MX345830B MX2014010589A MX2014010589A MX345830B MX 345830 B MX345830 B MX 345830B MX 2014010589 A MX2014010589 A MX 2014010589A MX 2014010589 A MX2014010589 A MX 2014010589A MX 345830 B MX345830 B MX 345830B
Authority
MX
Mexico
Prior art keywords
pyrimidine
compositions
methods
based compounds
pirazol
Prior art date
Application number
MX2014010589A
Other languages
English (en)
Other versions
MX2014010589A (es
Inventor
Gordon Carson Kenneth
Cianchetta Giovanni
Bi Yingzhi
Alan Green Michael
Kumi Godwin
Main Alan
Zhang Yulian
Gregory Zipp Glenn
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of MX2014010589A publication Critical patent/MX2014010589A/es
Publication of MX345830B publication Critical patent/MX345830B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos a base de pirazol[1,5-a]pirimidina de la fórmula: (ver Fórmula) en donde R1, R2 y R3 se definen en la presente. También se describen las composiciones que comprenden los compuestos y métodos para su uso para tratar, manejar y/o prevenir enfermedades y trastornos mediados por la actividad de cinasa 1 asociada al adaptador.
MX2014010589A 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. MX345830B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (2)

Publication Number Publication Date
MX2014010589A MX2014010589A (es) 2014-09-18
MX345830B true MX345830B (es) 2017-02-17

Family

ID=47892052

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010589A MX345830B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
MX2017002117A MX381849B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017002117A MX381849B (es) 2012-03-09 2013-03-05 Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.

Country Status (25)

Country Link
US (3) US8946415B2 (es)
EP (1) EP2834243B1 (es)
JP (1) JP6418950B2 (es)
KR (1) KR101965025B1 (es)
CN (1) CN104302649B (es)
AR (1) AR090292A1 (es)
AU (1) AU2013230128B2 (es)
BR (1) BR112014022000A8 (es)
CA (1) CA2866143C (es)
DK (1) DK2834243T3 (es)
ES (1) ES2676224T3 (es)
HU (1) HUE038786T2 (es)
IL (1) IL234486A (es)
IN (1) IN2014DN07384A (es)
MX (2) MX345830B (es)
NZ (1) NZ630721A (es)
PL (1) PL2834243T3 (es)
PT (1) PT2834243T (es)
RU (1) RU2014140735A (es)
SG (1) SG11201405561RA (es)
TR (1) TR201808280T4 (es)
TW (1) TW201341386A (es)
UY (1) UY34668A (es)
WO (1) WO2013134228A1 (es)
ZA (1) ZA201406149B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
HUE038786T2 (hu) 2012-03-09 2018-11-28 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-alapú vegyületek, ezeket tartalmazó kompozíciók és eljárások alkalmazásukra
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN110317214B (zh) 2014-01-24 2022-11-22 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
US9932320B2 (en) * 2014-01-31 2018-04-03 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
AU2015365587B2 (en) * 2014-12-15 2020-07-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as TRK inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
JP6817287B2 (ja) 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キラルジアリール大環状分子及びその使用
SG11201803605YA (en) 2015-11-02 2018-05-30 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
US10947242B2 (en) 2016-11-02 2021-03-16 Janssen Pharmaceutica, Nv [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
CA3038916A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
WO2018083101A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
EP3724191B9 (en) * 2017-12-15 2022-05-18 Pyramid Biosciences, Inc. 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
JOP20200152A1 (ar) 2017-12-19 2022-10-30 Turning Point Therapeutics Inc مركبات حلقية كبرى لعلاج مرض
JP7150356B2 (ja) * 2017-12-22 2022-10-11 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ［１，５－ａ］ピリミジン化合物並びにその医薬組成物および使用
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
EP3856743A4 (en) * 2018-09-27 2022-06-15 Fochon Pharmaceuticals, Ltd. SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2021216441A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
EP4138844A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
WO2025054448A1 (en) * 2023-09-08 2025-03-13 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PT2725028T (pt) * 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
US8946237B2 (en) * 2010-01-14 2015-02-03 Merck Sharp & Dohme Corp. Pyrazolo[1,5-A]pyrimidines as mark inhibitors
ES2671748T3 (es) * 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
PL2822555T3 (pl) * 2012-03-09 2018-04-30 Lexicon Pharmaceuticals Inc Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu
HUE038786T2 (hu) 2012-03-09 2018-11-28 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-alapú vegyületek, ezeket tartalmazó kompozíciók és eljárások alkalmazásukra
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
CA2866143C (en) 2020-08-04
SG11201405561RA (en) 2014-10-30
KR101965025B1 (ko) 2019-04-02
US20150183792A1 (en) 2015-07-02
MX381849B (es) 2025-03-13
CN104302649A (zh) 2015-01-21
JP6418950B2 (ja) 2018-11-07
ES2676224T3 (es) 2018-07-17
IN2014DN07384A (es) 2015-04-24
WO2013134228A1 (en) 2013-09-12
UY34668A (es) 2013-10-31
PT2834243T (pt) 2018-08-01
DK2834243T3 (en) 2018-07-23
TR201808280T4 (tr) 2018-07-23
US9403832B2 (en) 2016-08-02
US20170129896A1 (en) 2017-05-11
CA2866143A1 (en) 2013-09-12
TW201341386A (zh) 2013-10-16
MX2014010589A (es) 2014-09-18
ZA201406149B (en) 2016-06-29
US20130253194A1 (en) 2013-09-26
BR112014022000A8 (pt) 2021-06-15
AR090292A1 (es) 2014-11-05
EP2834243B1 (en) 2018-04-25
AU2013230128B2 (en) 2017-08-17
EP2834243A1 (en) 2015-02-11
CN104302649B (zh) 2017-06-23
HK1201257A1 (en) 2015-08-28
US8946415B2 (en) 2015-02-03
BR112014022000A2 (pt) 2017-06-20
JP2015509535A (ja) 2015-03-30
IL234486A (en) 2016-10-31
KR20140138864A (ko) 2014-12-04
HUE038786T2 (hu) 2018-11-28
RU2014140735A (ru) 2016-04-27
AU2013230128A1 (en) 2014-09-25
PL2834243T3 (pl) 2018-09-28
NZ630721A (en) 2016-12-23

Similar Documents

Publication Publication Date Title
MX345830B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
GT201400196A (es) Compuestos de heterociclilo
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CR20190156A (es) Derivados de bipirazol como inhibidores jak
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
MX2019005154A (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
ECSP16074478A (es) Compuestos novedosos
ECSP15025093A (es) Derivados de Oxazolidin-2-ona-Pirimidina
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores
UY33584A (es) Nuevos compuestos benzamida de inhibidores lrrk2
CU20100174A7 (es) Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados de pirazol[1,5-a]pirimidinas, procedimiento para su preparación y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration